Skip to main content
. Author manuscript; available in PMC: 2011 Jul 30.
Published in final edited form as: Biochem Biophys Res Commun. 2010 Jun 22;398(3):377–382. doi: 10.1016/j.bbrc.2010.06.075

Fig. 2.

Fig. 2

Recombinant tPTD-HoxB4 fusion protein increased the expression of CD61 and CD41a during Mk development from CD34 positively-selected cord blood cells by primarily increasing TpoR expression and decreasing c-Myb expression. (A) Percentages of CD61 or CD41a positive cells on Day 5. (B) Percentages of CD61 or CD41a positive cells on Day 8. (C) Absolute numbers of CD61 or CD41a positive cells on Day 5. (D) Absolute numbers of CD61 or CD41a positive cells on Day 8. (E) Cell growth was inhibited by HoxB4 fusion protein. (F) Gene expression on Day 8. Data is from two independent experiments.